При пациенти, лекувани с NeoRecormon, тази честота е 7% в сравнение с 4% при контролите.
In patients treated with NeoRecormon, this incidence is 7% compared to 4% in controls; this is not associated with any increase in thromboembolic mortality compared with controls.